Pyrrolo [2,3-b] pyridine derivatives
    41.
    发明授权
    Pyrrolo [2,3-b] pyridine derivatives 失效
    吡咯并[2,3-b]吡啶衍生物

    公开(公告)号:US07351708B2

    公开(公告)日:2008-04-01

    申请号:US11634563

    申请日:2006-12-06

    CPC分类号: C07D471/04

    摘要: The present invention relates to compounds of formula I wherein R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

    摘要翻译: 本发明涉及式I化合物,其中R 1至R 4如在说明书和权利要求书中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。

    Piperidine sulphonamide derivatives
    43.
    发明授权
    Piperidine sulphonamide derivatives 有权
    哌啶磺酰胺衍生物

    公开(公告)号:US08202888B2

    公开(公告)日:2012-06-19

    申请号:US12365911

    申请日:2009-02-05

    IPC分类号: A61K31/454 C07D401/06

    CPC分类号: C07D401/06 C07D211/96

    摘要: The present invention relates to piperidine sulphonamide derivatives of formula wherein Ar1, Ar2, R1, R2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula I are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.

    摘要翻译: 本发明涉及下式的哌啶磺酰胺衍生物其中Ar 1,Ar 2,R 1,R 2,m和n如说明书和权利要求中所定义,或其药学上合适的酸加成盐。 式I化合物是食欲蛋白受体拮抗剂,相关化合物可用于治疗睡眠呼吸暂停,发作性睡病,失眠,睡眠,夜间综合征,昼夜节律障碍或与神经疾病相关的睡眠障碍。

    (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones
    47.
    发明授权
    (Indol-4-yl) or (indol-5-yl)-piperazinylmethanones 失效
    (吲哚基-4-基)或(吲哚-5-基) - 哌嗪基甲酮

    公开(公告)号:US07557108B2

    公开(公告)日:2009-07-07

    申请号:US12018284

    申请日:2008-01-23

    CPC分类号: C07D209/08 C07D235/06

    摘要: The present invention relates to compounds of formula I wherein one of R1 and R2 is hydrogen and the other one is and wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

    摘要翻译: 本发明涉及式I化合物,其中R 1和R 2之一是氢,另一个是且其中A和R 1至R 4如说明书和权利要求中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。

    (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES
    50.
    发明申请
    (INDOL-4-YL) OR (INDOL-5-YL)-PIPERAZINYLMETHANONES 失效
    (INDOL-4-YL)或(INDOL-5-YL) - 哌嗪基甲基

    公开(公告)号:US20080188486A1

    公开(公告)日:2008-08-07

    申请号:US12018284

    申请日:2008-01-23

    CPC分类号: C07D209/08 C07D235/06

    摘要: The present invention relates to compounds of formula I wherein one of R1 and R2 is hydrogen and the other one is and wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

    摘要翻译: 本发明涉及式I化合物,其中R 1和R 2之一是氢,另一个是且其中A和R 1, R 4和R 4如在说明书和权利要求书中所定义,及其药学上可接受的盐。 该化合物可用于治疗和/或预防与H3受体的调节相关的疾病。